All News

Vaccination,vaccine

Downside of Holding Methotrexate with COVID-19 Vaccination

Jack Cush, MD

A recent prospective, randomized, blinded clinical trial has shown that a 2 week hold of methotrexate (MTX) following COVID-19 (Sinovac-CoronaVac) vaccination resulted in greater anti-SARS-CoV-2 immunogenicity; but there was an increase in flare rates after the second dose of vaccine.

Read Article
PSA2L.jpg

COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis

Jack Cush, MD

Guselkumab, an IL-2319-subunit antibody, was studied in active psoriatic arthritis (PsA) patients who had a previously inadequate response (IR) to tumour necrosis factor inhibitors (TNFi) and after 1 year was shown to significantly improved joint and skin manifestations and physical function.

Read Article
COVID,vaccinate,injection,green

Low COVID-19 Vaccine Risks in Rheumatic Patients

Jack Cush, MD

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Read Article
PsA, PSO, nail

Two Year Guselkumab Benefits in Psoriatic Arthritis

MedPage Today

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.

Read Article
Pills.men_.jpg

Rheumatoid Arthritis Nonadherence is Multifactorial

Jack Cush, MD

The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging.  A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini

Read Article
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Jack Cush, MD

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
VitD_1.jpg

Vitamin D and the Risk of Autoimmune Diseases

Jack Cush, MD

The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.

Read Article
Referring Psoriasis with Joint Pain Psoriasis Patient with a Few Tender Joints - How to Refer to a Rheumatologist. QD Clinic is sponsored by RheumNow Live (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/kuDc6xi3NZ https://t.co/VCFFFqA040

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic fingernail onycholysis and hyperkeratosis, rather than nail pitting, are significantly & independently assoc w/ PsA. Study of 1985 pts w/psoriasis, 11.5% were Dx w/ PsA. Only onycholysis (OR 2.34) and hyperkeratosis ) were assoc w/ PsA https://t.co/X3JHUFtGdD https://t.co/xu8erkOMSa

Links:

Dr. John Cush RheumNow ( View Tweet)
COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis https://t.co/kl6RzE6hK2 https://t.co/vLY2xQAqwn

Links:

Dr. John Cush RheumNow ( View Tweet)
Case showing flare of Dermatomyositis in a Patient With Psoriasis treated with Secukinumab. https://t.co/uvXyqONaHl

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center study of 957 plaque psoriasis pts and the effect of air pollutants. Overall 39% experience a PSO flare and that concentrations of all pollutants were significantly higher in the 60 days before psoriasis flare https://t.co/8Hw3LsLy8f

Links:

Dr. John Cush RheumNow ( View Tweet)

NOR-DRUM study shows that TDM, therapeutic drug monitoring, is beneficial. Study of RA, PSA, AS, Crohn's, UC Rheums don't do this, should they? #RWCS2022 @RWCSmtg https://t.co/Dc6mgr5jrL
Dr. John Cush RheumNow ( View Tweet)
IMPACT2 shows what we see in most PSA trials- little x-ray progression. #RWCS2022 @RWCSmtg https://t.co/uYXHB0s8g0
Dr. John Cush RheumNow ( View Tweet)
Fecal transplant (FMT) failed to help #PsA, small trial, unexpected result. #RWCS2022 @RWCSmtg https://t.co/zKq6FONuwk
Dr. John Cush RheumNow ( View Tweet)
We have an exciting agenda for #RNL2022, with topics ranging from Psoriatic Disease for Rheumatologists to Advances in Psoriasis Management and speakers from around the world, including Dr. Bruce Strober. Register Today! https://t.co/VZ2hmxAmDw https://t.co/AJbSLNXDql

Links:

Dr. John Cush RheumNow ( View Tweet)
Data from 2 phase III studies of psoriatic arthritis using tofacitinib, adalimumab shows that a significant meaningful clinical response is achieved in 29-53 days -- why then are we not making go vs no-go decisions with modern biologics at 6-8 weeks? https://t.co/F56P9c3Rb5

Links:

Dr. John Cush RheumNow ( View Tweet)

Join Dr. Alexis Ogdie at RheumNow Live next month, as she leads a panel on RWE & Registries in Psoriatic Arthritis. Attend on-site in Texas or virtually! Invigorate, Instigate and Debate Rheumatology at #RNL2022 https://t.co/aTEWF9VsdN https://t.co/e2W5XpzztN

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevalence of PsA, axSpA & RA (2017) in Norwegian adults is 0.46%, 0.41%, & 0.78%. In 2017, 27.3% of RA patients, 25.7% of PsA patients and 35.1% of axSpA patients used biologic DMARDs (biologics more freq in youngers; infrequent if ≥55 yrs https://t.co/oqlpPmam6R

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Dr. Philip Mease will be joining us at RheumNow Live, leading a presentation and discussion on Axial Psoriatic Arthritis & Fatigue and Central Sensitization. Join the discussion on March 19-20, on site or virtually! https://t.co/3CeULLDgf5 https://t.co/M2ZUoXzlAK

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×